Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-20T01:01:53.266Z Has data issue: false hasContentIssue false

Chapter 38 - Cancer in the elderly

from Section III - Care of the elderly by organ system

Published online by Cambridge University Press:  05 June 2016

By
Caroline Mariano  and
Hyman Muss
Edited by
Jan Busby-Whitehead ,
Christine Arenson ,
Samuel C. Durso ,
Daniel Swagerty ,
Laura Mosqueda ,
Maria Fiatarone Singh  and
William Reichel
Jan Busby-Whitehead
Affiliation:
University of North Carolina
Christine Arenson
Affiliation:
Thomas Jefferson University, Philadelphia
Samuel C. Durso
Affiliation:
The Johns Hopkins University School of Medicine
Daniel Swagerty
Affiliation:
University of Kansas
Laura Mosqueda
Affiliation:
University of Southern California
Maria Fiatarone Singh
Affiliation:
University of Sydney
William Reichel
Affiliation:
Georgetown University, Washington DC
Get access

Summary

Cancer is one of the leading causes of mortality and morbidity in the developed world. Age is a primary risk factor for developing cancer, and geriatric oncology is a rapidly emerging field which aims to address the needs of older cancer patients. The four most common solid tumors encountered in elderly patients are breast, prostate, colorectal, and lung cancer. All clinicians who deal with elderly patients should have knowledge of cancer risks, screening, and management principles. When evaluating cancer patients, the first issue to address is life expectancy exclusive of the cancer diagnosis. After estimating life expectancy and completing a geriatric assessment, the goals and options of cancer treatment can be better defined. Final decision-making should be patient-centered, with the patient’s (and the family, if appropriate) choice taking precedence
Type
Chapter
Information
Reichel's Care of the Elderly
Clinical Aspects of Aging
 , pp. 537 - 563
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Shih, YC, Hurria, A. Preparing for an epidemic: cancer care in an aging population. Am Soc Clin Oncol Educ Book 2014;34:133–137.Google Scholar
Lopez-Otin, C, Blasco, MA, Partridge, L, et al. The hallmarks of aging. Cell 2013 Jun 6;153(6):1194–1217.CrossRefGoogle ScholarPubMed
Mariotto, AB, Yabroff, KR, Shao, Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011 Jan 19;103(2):117–128.Google Scholar
Fried, TR, Bradley, EH, Towle, VR, Allore, H. Understanding the treatment preferences of seriously ill patients. N Engl J Med 2002 Apr 4;346(14):1061–1066.Google Scholar
Ramsdale, E, Polite, B, Hemmerich, J, et al. The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study. J Am Geriatr Soc 2013 Nov;61(11):2043–2044.Google Scholar
Min, LC, Elliott, MN, Wenger, NS, Saliba, D. Higher vulnerable elders survey scores predict death and functional decline in vulnerable older people. J Am Geriatr Soc 2006 Mar;54(3):507–511.CrossRefGoogle ScholarPubMed
Hurria, A, Cirrincione, CT, Muss, HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 2011 Apr 1;29(10):1290–1296.Google Scholar
Hurria, A, Gupta, S, Zauderer, M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005 Nov 1;104(9):1998–2005.Google Scholar
Williams, GR, Deal, AM, Jolly, TA, et al. Feasibility of geriatric assessment in community oncology clinics. J Geriatr Oncol 2014 Jul;5(3):245–251.Google Scholar
Hurria, A, Togawa, K, Mohile, SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011 Sep 1;29(25):3457–3465.Google Scholar
Extermann, M, Boler, I, Reich, RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012 Jul 1;118(13):3377–3386.Google Scholar
Puts, MT, Santos, B, Hardt, J, et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol 2014 Feb;25(2):307–315.CrossRefGoogle ScholarPubMed
Soubeyran, P, Fonck, M, Blanc-Bisson, C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012 May 20;30(15):1829–1834.Google Scholar
Hutchins, LF, Unger, JM, Crowley, JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999 Dec 30;341(27):2061–2067.Google Scholar
Sacher, AG, Le, LW, Leighl, NB, Coate, LE. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol 2013 Mar;8(3):366–368.Google Scholar
Kemeny, MM, Peterson, BL, Kornblith, AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003 Jun 15;21(12):2268–2275.Google Scholar
Ferlay, J, Soerjomataram, I, Ervik, M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. 2012;11. Available at: http://globocan.iarc.fr (accessed Jan 15, 2014).Google Scholar
Howlader, N, Noone, A, Krapcho, M, et al. SEER Cancer Statistics Review, 1975–2010, based on November 2012 SEER data. Available at: http://seer.cancer.gov/csr/1975_2010 (accessed Jan 15, 2014).Google Scholar
Walter, LC, Schonberg, MA. Screening mammography in older women: a review. JAMA 2014 Apr 2;311(13):1336–1347.Google Scholar
Van der Kolk, DM, de Bock, GH, Leegte, BK, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010 Dec;124(3):643–651.Google Scholar
Cummings, SR, Lee, JS, Lui, LY, et al. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev 2005 May;14(5):1047–1051.Google Scholar
Rossouw, JE, Anderson, GL, Prentice, RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 Jul 17;288(3):321–333.Google Scholar
Van den Brandt, PA, Spiegelman, D, Yaun, SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000 Sep 15;152(6):514–527.CrossRefGoogle ScholarPubMed
Lynch, B, Neilson, H, Friedenreich, C. Physical activity and breast cancer prevention. Recent Results Cancer Res 2011;186:13–42.Google Scholar
Chen, WY, Rosner, B, Hankinson, SE, et al. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 2011 Nov 2;306(17):1884–1890.Google Scholar
Travis, LB, Hill, DA, Dores, GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003 Jul 23;290(4):465–475.Google Scholar
Pukkala, E, Kesminiene, A, Poliakov, S, et al. Breast cancer in Belarus and Ukraine after the Chernobyl accident. Int J Cancer 2006 Aug 1;119(3):651–658.Google Scholar
Wishart, GC, Bajdik, CD, Dicks, E, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012 Aug 21;107(5):800–807.CrossRefGoogle ScholarPubMed
Nelson, HD, Tyne, K, Naik, A, et al. Screening for breast cancer: an update for the US Preventive Services Task Force. Ann Intern Med 2009 Nov 17;151(10):727–737, W237–W242.Google Scholar
Durso, S, Sullivan, G editors. Geriatrics Review Syllabus, 8th ed. New York: American Geriatric Society; 2013.Google Scholar
Visvanathan, K, Hurley, P, Bantug, E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013 Aug 10;31(23):2942–2962.Google Scholar
Moyer, VA, US Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the US Preventive Services Task Force recommendation statement. Ann Intern Med 2013 Nov 19;159(10):698–708.Google Scholar
National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (accessed Nov 1, 2013).Google Scholar
Siegel, R, Ma, J, Zou, Z, Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 2014 Jan;64(1):9–29.Google Scholar
Ravdin, PM, Siminoff, LA, Davis, GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001 Feb 15;19(4):980–991.Google Scholar
Kong, I, Narod, SA, Taylor, C, et al. Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. Curr Oncol 2014 Feb;21(1):e96–e104.CrossRefGoogle ScholarPubMed
Hind, D, Wyld, L, Beverley, CB, Reed, MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006 Jan 25;1:CD004272.Google Scholar
Hughes, KS, Schnaper, LA, Bellon, JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013 Jul 1;31(19):2382–2387.CrossRefGoogle ScholarPubMed
The PRIME II trial: Wide local excision and adjuvant hormonal therapy ± postoperative whole breast irradiation in women ≥ 65 years with early breast cancer managed by breast conservation. Abstract S2–01. 36th Annual San Antonio Breast Cancer Symposium; December 2013.Google Scholar
Biganzoli, L, Wildiers, H, Oakman, C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012 Apr;13(4):e148–e160.Google Scholar
Burstein, HJ, Prestrud, AA, Seidenfeld, J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010 Aug 10;28(23):3784–3796.CrossRefGoogle Scholar
Davies, C, Pan, H, Godwin, J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013 Mar 9;381(9869):805–816.Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto, R, Davies, C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012 Feb 4;379(9814):432–444.Google Scholar
Muss, HB, Woolf, S, Berry, D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005 Mar 2;293(9):1073–1081.Google Scholar
Albanell, J, Ciruelos, EM, Lluch, A, et al. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev 2014 Feb;40(1):41–47.Google Scholar
Chavez-MacGregor, M, Zhang, N, Buchholz, TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013 Nov 20;31(33):4222–4228.Google Scholar
Hutchinson, AD, Hosking, JR, Kichenadasse, G, et al. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 2012 Nov;38(7):926–934.Google Scholar
Mandelblatt, JS, Jacobsen, PB, Ahles, T. Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. J Clin Oncol 2014 Aug 20;32(24):2617–2626.Google Scholar
Macaskill, EJ, Renshaw, L, Dixon, JM. Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer. Oncologist 2006 Nov–Dec;11(10):1081–1088.Google Scholar
Khatcheressian, JL, Hurley, P, Bantug, E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013 Mar 1;31(7):961–965.Google Scholar
Rock, CL, Demark-Wahnefried, W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 2002 Aug 1;20(15):3302–3316.Google Scholar
Rock, CL, Doyle, C, Demark-Wahnefried, W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012 Jul–Aug;62(4):243–274.Google Scholar
Delongchamps, NB, Singh, A, Haas, GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control 2006 Jul;13(3):158–168.Google Scholar
Hoffman, RM, Gilliland, FD, Eley, JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001 Mar 7;93(5):388–395.Google Scholar
Zheng, SL, Sun, J, Wiklund, F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008 Feb 28;358(9):910–919.Google Scholar
Kenfield, SA, Stampfer, MJ, Chan, JM, Giovannucci, E. Smoking and prostate cancer survival and recurrence. JAMA 2011 Jun 22;305(24):2548–2555.Google Scholar
Yan, L, Spitznagel, EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr 2009 Apr;89(4):1155–1163.Google Scholar
Schroder, FH, Hugosson, J, Roobol, MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012 Mar 15;366(11):981–990.Google Scholar
Andriole, GL, Crawford, ED, Grubb, RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012 Jan 18;104(2):125–132.Google Scholar
Drazer, MW, Prasad, SM, Huo, D, et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer 2014 May 15;120(10):1491–1498.Google Scholar
Moyer, VA, US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012 Jul 17;157(2):120–134.Google Scholar
AJCC (American Joint Committee on Cancer). Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2010.Google Scholar
Sun, L, Caire, AA, Robertson, CN, et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009 Nov;182(5):2242–2248.Google Scholar
Keyes, M, Crook, J, Morton, G, et al. Treatment options for localized prostate cancer. Can Fam Physician 2013 Dec;59(12):1269–1274.Google Scholar
Alemozaffar, M, Regan, MM, Cooperberg, MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011 Sep 21;306(11):1205–1214.Google Scholar
Shappley, WV 3rd, Kenfield, SA, Kasperzyk, JL, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009 Oct 20;27(30):4980–4985.Google Scholar
Trinh, QD, Bjartell, A, Freedland, SJ, et al. A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol 2013 Nov;64(5):786–798.Google Scholar
Vordermark, D. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008 Jul 10;359(2):201; author reply 201–2.Google Scholar
Resnick, MJ, Koyama, T, Fan, KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013 Jan 31;368(5):436–445.Google Scholar
Schulman, C, Irani, J, Aapro, M. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy. BJU Int 2012 Jun;109(Suppl 6):13–21.Google Scholar
Hussain, M, Tangen, CM, Berry, DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013 Apr 4;368(14):1314–1325.Google Scholar
Crook, JM, O’Callaghan, CJ, Duncan, G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012 Sep 6;367(10):895–903.CrossRefGoogle ScholarPubMed
Italiano, A, Ortholan, C, Oudard, S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009 Jun;55(6):1368–1375.Google Scholar
Mukherji, D, Pezaro, CJ, Shamseddine, A, De Bono, JS. New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treat Rev 2013 Oct;39(6):578–583.Google Scholar
Papamichael, D, Audisio, R, Horiot, JC, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009 Jan;20(1):5–16.CrossRefGoogle ScholarPubMed
Atkin, WS, Morson, BC, Cuzick, J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992 Mar 5;326(10):658–662.CrossRefGoogle ScholarPubMed
Kitahara, CM, Berndt, SI, de Gonzalez, AB, et al. Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol 2013 Jul 1;31(19):2450–2459.Google Scholar
Boyle, T, Keegel, T, Bull, F, et al. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst 2012 Oct 17;104(20):1548–1561.CrossRefGoogle ScholarPubMed
Rex, DK, Johnson, DA, Anderson, JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009 Mar;104(3):739–750.Google Scholar
US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2008 Nov 4;149(9):627–637.Google Scholar
Lee, SJ, Leipzig, RM, Walter, LC. Incorporating lag time to benefit into prevention decisions for older adults. JAMA 2013 Dec 25;310(24):2609–2610.CrossRefGoogle ScholarPubMed
Gross, CP, Soulos, PR, Ross, JS, et al. Assessing the impact of screening colonoscopy on mortality in the medicare population. J Gen Intern Med 2011 Dec;26(12):1441–1449.Google Scholar
Hewitson, P, Glasziou, P, Watson, E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008 Jun;103(6):1541–1549.Google Scholar
Lieberman, DA, Weiss, DG, Bond, JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000 Jul 20;343(3):162–168.Google Scholar
Colorectal Cancer Collaborative Group. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 2000 Sep 16;356(9234):968–974.Google Scholar
Hoffman, RM, Walter, LC. Colorectal cancer screening in the elderly: the need for informed decision making. J Gen Intern Med 2009 Dec;24(12):1336–1337.Google Scholar
Rothwell, PM, Wilson, M, Elwin, CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010 Nov 20;376(9754):1741–1750.Google Scholar
Majumdar, SR, Fletcher, RH, Evans, AT. How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol 1999 Oct;94(10):3039–3045.CrossRefGoogle ScholarPubMed
Gill, S, Loprinzi, C, Kennecke, H, et al. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer 2011 Sep 15;117(18):4155–4165.CrossRefGoogle ScholarPubMed
Benson, AB 3rd, Schrag, D, Somerfield, MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004 Aug 15;22(16):3408–3419.Google Scholar
Andre, T, Boni, C, Mounedji-Boudiaf, L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004 Jun 3;350(23):2343–2351.Google Scholar
Tournigand, C, Andre, T, Bonnetain, F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012 Sep 20;30(27):3353–3360.Google Scholar
Sanoff, HK, Carpenter, WR, Martin, CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012 Feb 8;104(3):211–227.Google Scholar
Muss, HB, Bynum, DL. Adjuvant chemotherapy in older patients with stage III colon cancer: an underused lifesaving treatment. J Clin Oncol 2012 Jul 20;30(21):2576–2578.Google Scholar
Meyerhardt, JA, Mangu, PB, Flynn, PJ, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 2013 Dec 10;31(35):4465–4470.Google Scholar
Chibaudel, B, Tournigand, C, Andre, T, de Gramont, A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol 2012 Mar;4(2):75–89.Google Scholar
Seymour, MT, Thompson, LC, Wasan, HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011 May 21;377(9779):1749–1759.Google Scholar
Samet, JM, Wiggins, CL, Humble, CG, Pathak, DR. Cigarette smoking and lung cancer in New Mexico. Am Rev Respir Dis 1988 May;137(5):1110–1113.Google Scholar
Centers for Disease Control and Prevention (CDC). State-specific prevalence of current cigarette smoking among adults, and policies and attitudes about secondhand smoke – United States, 2000. MMWR Morb Mortal Wkly Rep 2001 Dec 14;50(49):1101–1106.Google Scholar
Brenner, DR, Boffetta, P, Duell, EJ, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol 2012 Oct 1;176(7):573–585.Google Scholar
Omenn, GS, Goodman, GE, Thornquist, MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996 May 2;334(18):1150–1155.CrossRefGoogle ScholarPubMed
World Health Organization. WHO report on the global tobacco epidemic, 2013: enforcing bans on tobacco advertising, promotion and sponsorship; 2013. Available at: www.who.int/tobacco/global_report/2013/en.Google Scholar
Parsons, A, Daley, A, Begh, R, Aveyard, P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010 Jan 21;340:b5569.Google Scholar
National Lung Screening Trial Research Team, Aberle, DR, Adams, AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011 Aug 4;365(5):395–409.Google ScholarPubMed
McWilliams, A, Tammemagi, MC, Mayo, JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013 Sep 5;369(10):910–919.Google Scholar
Moyer, VA. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2013 Dec 31;160(5):330–338.Google Scholar
Chute, CG, Greenberg, ER, Baron, J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985 Oct 15;56(8):2107–2111.Google Scholar
Detterbeck, FC, Postmus, PE, Tanoue, LT. The stage classification of lung cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013 May;143(5 Suppl):e191S–210S.Google Scholar
Grills, IS, Mangona, VS, Welsh, R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010 Feb 20;28(6):928–935.Google Scholar
Senthi, S, Lagerwaard, FJ, Haasbeek, CJ, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012 Aug;13(8):802–809.CrossRefGoogle ScholarPubMed
Butts, CA, Ding, K, Seymour, L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010 Jan 1;28(1):29–34.Google Scholar
Fruh, M, Rolland, E, Pignon, JP, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008 Jul 20;26(21):3573–3581.Google Scholar
Hardy, D, Cormier, JN, Xing, Y, et al. Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer. J Thorac Oncol 2010 Jan;5(1):90–98.Google Scholar
Schild, SE, Mandrekar, SJ, Jatoi, A, et al. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer 2007 Jul 15;110(2):363–368.Google Scholar
NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008 Oct 1;26(28):4617–4625.Google Scholar
Quoix, E, Zalcman, G, Oster, JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011 Sep 17;378(9796):1079–1088.CrossRefGoogle ScholarPubMed
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer: the Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999 Jan 6;91(1):66–72.CrossRefGoogle Scholar
Ramalingam, SS, Dahlberg, SE, Langer, CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008 Jan 1;26(1):60–65.Google Scholar
Mok, T, Wu, Y, Thongprasert, S, et al. Phase III, randomised, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced nonsmall-cell lung cancer (IPASS). Ann Oncol 2010;21 (Suppl 8): 1.Google Scholar
Temel, JS, Greer, JA, Muzikansky, A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010 Aug 19;363(8):733–742.Google Scholar
Gaspar, LE, Gay, EG, Crawford, J, et al. Limited-stage small-cell lung cancer (stages I–III): observations from the National Cancer Data Base. Clin Lung Cancer 2005 May;6(6):355–360.Google Scholar
Eaton, BR, Kim, S, Marcus, DM, et al. Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer. Cancer 2013 Nov 1;119(21):3753–3760.Google Scholar
Dietrich, J, Monje, M, Wefel, J, Meyers, C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008 Dec;13(12):1285–1295.Google Scholar
Parikh, RB, Temel, JS. Early specialty palliative care. N Engl J Med 2014 Mar 13;370(11):1075–1076.Google Scholar
Medicare hospice benefits. 2013 August 2013;02154. Available at: www.medicare.gov.Google Scholar
Feldt, KS. The checklist of nonverbal pain indicators (CNPI). Pain Manag Nurs 2000 Mar;1(1):13–21.Google Scholar
Schuler, MS, Becker, S, Kaspar, R, et al. Psychometric properties of the German “Pain Assessment in Advanced Dementia Scale” (PAINAD-G) in nursing home residents. J Am Med Dir Assoc 2007 Jul;8(6):388–395.Google Scholar
Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia: NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. JAMA 1996 Jul 24–31;276(4):313–318.Google Scholar
Randomized trial of exercise vs usual care on aromatase inhibitor-associated arthralgias in women with breast cancer. Abstract S3–03. San Antonio Breast Cancer Symposium 2013; December 2013.Google Scholar
Basch, E, Prestrud, A, Hesketh, P, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011 November 1 2011;29(31):4189–4198.Google Scholar
Cancer Care Ontario Symptom Assessment and Management Tools. 2014; Available at: www.cancercare.on.ca/toolbox/symptools (accessed on Jan 15, 2014).Google Scholar
Barford, K, D’Olimpio, J. Symptom management in geriatriconcology: practical treatment considerations and current challenges. Curr Treat Options Oncol 2008 June 2008;9(2):204–214.Google Scholar
Librach, SL, Bouvette, M, De Angelis, C, et al. Consensus recommendations for the management of constipation in patients with advanced, progressive illness. J Pain Symptom Manage 2010 Nov;40(5):761–773.Google Scholar
Smith, EM, Pang, H, Cirrincione, C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013 Apr 3;309(13):1359–1367.CrossRefGoogle ScholarPubMed
Galbraith, S, Fagan, P, Perkins, P, et al. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage 2010 May;39(5):831–838.Google Scholar
Ben-Aharon, I, Gafter-Gvili, A, Paul, M, et al. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008 May 10;26(14):2396–2404.Google Scholar
Hallenbeck, J. Pathophysiologies of dyspnea explained: why might opioids relieve dyspnea and not hasten death? J Palliat Med 2012 Aug;15(8):848–853.Google Scholar
Hurria, A, Naylor, M, Cohen, HJ. Improving the quality of cancer care in an aging population: recommendations from an IOM report. JAMA 2013 Nov 6;310(17):1795–1796.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×